SENTI BIOSCIENCES INC (SNTI) Stock Price, Quote, News and Overview
NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD
SNTI Quote, Performance and Key Statistics
NASDAQ:SNTI (2/21/2025, 12:02:08 PM)
3.97
-0.02 (-0.5%)
The current stock price of SNTI is 3.97 USD. In the past month the price decreased by -12.69%. In the past year, price decreased by -2.71%.
SNTI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 357.78B | ||
| AMGN | AMGEN INC | 15.17 | 161.48B | ||
| GILD | GILEAD SCIENCES INC | 23.98 | 137.74B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1672.81 | 124.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.36B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.42B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.73B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.18B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.52 | 20.44B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.84B |
Related stock screener links
About SNTI
Company Profile
Senti Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 48 full-time employees. The company went IPO on 2021-05-26. Senti Biosciences, Inc. is a clinical-stage biotechnology company. The company is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Company Info
SENTI BIOSCIENCES INC
2 Corporate Drive, First Floor
South San Francisco CALIFORNIA US
Employees: 48
Company Website: https://www.sentibio.com/
Investor Relations: https://investors.sentibio.com/
Phone: 16503823281
SENTI BIOSCIENCES INC / SNTI FAQ
What is the stock price of SENTI BIOSCIENCES INC today?
The current stock price of SNTI is 3.97 USD. The price decreased by -0.5% in the last trading session.
What is the ticker symbol for SENTI BIOSCIENCES INC stock?
The exchange symbol of SENTI BIOSCIENCES INC is SNTI and it is listed on the Nasdaq exchange.
On which exchange is SNTI stock listed?
SNTI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SENTI BIOSCIENCES INC stock?
7 analysts have analysed SNTI and the average price target is 12.24 USD. This implies a price increase of 208.31% is expected in the next year compared to the current price of 3.97. Check the SENTI BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SENTI BIOSCIENCES INC worth?
SENTI BIOSCIENCES INC (SNTI) has a market capitalization of 19.18M USD. This makes SNTI a Nano Cap stock.
How many employees does SENTI BIOSCIENCES INC have?
SENTI BIOSCIENCES INC (SNTI) currently has 48 employees.
What are the support and resistance levels for SENTI BIOSCIENCES INC (SNTI) stock?
SENTI BIOSCIENCES INC (SNTI) has a support level at 3.79 and a resistance level at 4.02. Check the full technical report for a detailed analysis of SNTI support and resistance levels.
Is SENTI BIOSCIENCES INC (SNTI) expected to grow?
The Revenue of SENTI BIOSCIENCES INC (SNTI) is expected to grow by 21.74% in the next year. Check the estimates tab for more information on the SNTI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SENTI BIOSCIENCES INC (SNTI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNTI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNTI, evaluating the profitability, health, valuation and growth aspects
- SENTI BIOSCIENCES INC (SNTI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SENTI BIOSCIENCES INC (SNTI) Sales and EPS estimates to see what analysts future expectations are.
- SENTI BIOSCIENCES INC (SNTI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SENTI BIOSCIENCES INC (SNTI) Insider and Institutional Ownership to learn about the owners and their transactions.
- SENTI BIOSCIENCES INC (SNTI) Stock Chart to make your own analysis
- SENTI BIOSCIENCES INC (SNTI) Latest news and press-releases to stay up to date.
Does SENTI BIOSCIENCES INC (SNTI) stock pay dividends?
SNTI does not pay a dividend.
What is the Price/Earnings (PE) ratio of SENTI BIOSCIENCES INC (SNTI)?
SENTI BIOSCIENCES INC (SNTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.59).
What is the Short Interest ratio of SENTI BIOSCIENCES INC (SNTI) stock?
The outstanding short interest for SENTI BIOSCIENCES INC (SNTI) is 2.56% of its float. Check the ownership tab for more information on the SNTI short interest.
SNTI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SNTI. When comparing the yearly performance of all stocks, SNTI is one of the better performing stocks in the market, outperforming 92.07% of all stocks.
SNTI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNTI. SNTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNTI Financial Highlights
Over the last trailing twelve months SNTI reported a non-GAAP Earnings per Share(EPS) of -15.59. The EPS decreased by -893.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.83% | ||
| ROE | -443.27% | ||
| Debt/Equity | 0 |
SNTI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SNTI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -848.26% and a revenue growth 21.74% for SNTI